Biomarker evaluation in phase I clinical trials of selective PI3K and PI3k/mTOR inhibitors

被引：0
|
作者：
Spoerke, Jill [1 ]
Desai, Rupal [1 ]
Patel, Rajesh [1 ]
Fredrickson, Jill [1 ]
Wang, Yulei [1 ]
Levy, Gallia [1 ]
Gendreau, Steve [1 ]
Lauchle, Jennifer [1 ]
Derynck, Mika [1 ]
Raja, Rajiv [1 ]
Koeppen, Hartmut [1 ]
Hampton, Garret [1 ]
Yan, Yibing [1 ]
Lackner, Mark R. [1 ]
机构：
[1] Genentech Inc, San Francisco, CA 94080 USA
来源：
CANCER RESEARCH | 2013年 / 73卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2013-4567
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4567
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Biomarker evaluation In phase I clinical trials of selective PI3K and PI3K/mTOR inhibitors
    Spoerke, Jill
    O'Brien, Carol
    Wu, Jenny
    Desai, Rupal
    Patel, Rajesh
    Raja, Rajiv
    Koeppen, Hartmut
    Amler, Lukas
    Hampton, Garret
    Yan, Yibing
    Lackner, Mark R.
    CANCER RESEARCH, 2012, 72
  • [2] Pharmacodynamic biomarker evaluation in phase I clinical trials of selective PI3K and PI3K/mTOR inhibitors
    Nakanishi, Yoshito
    Spoerke, Jill M.
    Derynck, Mika
    Lauchle, Jennifer O.
    Koeppen, Hartmut
    Fredrickson, Jill
    Ware, Joseph
    Hampton, Garret
    Yan, Yibing
    Lackner, Mark R.
    MOLECULAR CANCER THERAPEUTICS, 2015, 14 (07)
  • [3] Discovery, Optimization, and Evaluation of Potent and Highly Selective PI3Kγ-PI3Kδ Dual Inhibitors
    Jia, Hong
    Dai, Guangxiu
    Su, Weiguo
    Xiao, Kun
    Weng, Jianyang
    Zhang, Zhulin
    Wang, Qing
    Yuan, Tianhai
    Shi, Fuying
    Zhang, Zheng
    Chen, Wei
    Sai, Yang
    Wang, Jian
    Li, Xiong
    Cai, Yu
    Yu, Jun
    Ren, Ping
    Venable, Jennifer
    Rao, Tadimeti
    Edwards, James P.
    Bembenek, Scott D.
    JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (10) : 4936 - 4948
  • [4] Activation of PI3K/Akt/mTOR Pathway and Dual Inhibitors of PI3K and mTOR in Endometrial Cancer
    Chen, Jiezhong
    Zhao, Kong-Nan
    Li, Rui
    Shao, Renfu
    Chen, Chen
    CURRENT MEDICINAL CHEMISTRY, 2014, 21 (26) : 3070 - 3080
  • [5] Biological characterization of SN32976, a selective inhibitor of PI3K and mTOR with preferential activity to PI3Kα, in comparison to established pan PI3K inhibitors
    Rewcastle, Gordon W.
    Kolekar, Sharada
    Buchanan, Christina M.
    Gamage, Swarna A.
    Giddens, Anna C.
    Tsang, Kit Y.
    Kendall, Jackie D.
    Singh, Ripudaman
    Lee, Woo-Jeong
    Smith, Greg C.
    Han, Weiping
    Matthews, David J.
    Denny, William A.
    Shepherd, Peter R.
    Jamieson, Stephen M. F.
    ONCOTARGET, 2017, 8 (29) : 47725 - 47740
  • [6] Designing selective PI3K inhibitors
    Sarah Crunkhorn
    Nature Reviews Drug Discovery, 2010, 9 : 105 - 105
  • [7] Designing selective PI3K inhibitors
    Crunkhorn, Sarah
    NATURE REVIEWS DRUG DISCOVERY, 2010, 9 (02) : 105 - 105
  • [8] Selective PI3K and dual PI3K/mTOR inhibitors enhance the efficacy of endocrine therapies in breast cancer models
    Friedman, L.
    Ross, L. B.
    Wallin, J.
    Guan, J.
    Prior, W. W.
    Wu, E.
    Nannini, M.
    Sampath, D.
    CANCER RESEARCH, 2012, 72
  • [9] THE ROLE OF CDK AND PI3K/MTOR INHIBITORS
    Andre, Fabrice
    BREAST, 2015, 24 : S25 - S25
  • [10] Predictive and pharmacodynamic (PD) markers of PI3K pathway inhibitors: focus on PI3K, AKT and mTOR inhibitors
    Tabernero, J.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S6 - S6
12345